Pfizer said Wednesday its Covid-19 vaccine was robustly effective in kids, demonstrating 100% efficacy in a phase three clinical trial testing its shot in adolescents aged 12 to 15.
Pfizer CEO Albert Bourla said the company plans to submit the new data on the vaccine, which is developed in partnership with German drugmaker BioNTech, to the Food and Drug Administration and other regulators “as soon as possible,” with the hope that kids in the age group will be able to get vaccinated before the start of the new school year.
“We share the urgency to expand the authorization of our vaccine to use in younger populations and
are encouraged by the clinical trial data from adolescents between the ages of 12 and 15,” Bourla said in a press release.
The trial enrolled 2,260 participants in the United States. There were 18 confirmed Covid-19 infections observed in the placebo group and no confirmed infections in the group that received the vaccine, the company said. That resulted in a vaccine efficacy of 100%, it said, adding that the shot was also well-tolerated, with side effects generally consistent with those seen in adults.
The company also said the vaccine elicited a “robust” antibody response in children, exceeding those recorded earlier in vaccinated participants aged 16 to 25 years old.
Vaccinating children is crucial to ending the pandemic, public health officials and infectious disease experts say. The nation is unlikely to achieve herd immunity – when enough people in a given community have antibodies against a specific disease – until children can get vaccinated, experts say.
Children make up around 20% of the U.S. population, according to government data. Between 70% and 85% of the U.S. population needs to be vaccinated against Covid to achieve herd immunity, experts say, and some adults may refuse to get the shots.
Pfizer’s vaccine has already been authorized for use in the U.S. in people 16 and older. Clinical trial studies testing the vaccine in kids, whose immune systems can respond differently than adults, still needed to be completed.
The White House’s chief medical advisor, Dr. Anthony Fauci, told a House committee earlier this month that the U.S. could begin vaccinating older kids against Covid-19 this fall while elementary-aged children may start getting their shots early next year.
Pfizer announced last week it started a clinical trial testing its Covid-19 vaccine on healthy 6-month to 11-year old children.
For the first phase of that trial, the company will identify the preferred dosing level for three age groups – between 6 months and 2 years old, 2 and 5 and from 5 through age 11. The kids will begin by receiving a 10 microgram dose of the vaccine before progressively moving to higher doses, according to the company. Participants also have the option to take 3 microgram doses.
Pfizer said Wednesday it plans to request an amendment to its current emergency use authorization with the FDA to include adolescents 12 to 15 years of age. All participants in the trial will continue to be monitored for an additional two years after their second dose, the company said.
Pfizer and BioNTech said they plan to submit the data for scientific peer review.